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We show that drugs, such as verapamil, which reverse multidrug resistance (MDR), in P-glycoprotein-overexpressing 
tumor cells, increased the rate of lactate production in four human MDR cell lines, but not in the parent, sensitive cell 
lines. The effect on glycolytic rate was maximal at a medium concentration of 2 PM verapamil. The glycolytic rate in 
sensitive (A2780) and MDR (278wD) cells showed the same pH dependence, but the effect of verapamil was seen only 
in 2780AD cells at all pH values investigated (6.6, 7.4 and 8.2). A series of drugs such as nigericin, oligomycin, amiloride 
and monensin had similar effects in the two cells. Phorbol my&ate acetate increased lactate formation in neither cell 
line. Verapamil induced an extra amount of ATP consumption in P-glycoprotein-expressing 2780AD cells of approx. 25 
pmol/s per 106 cells, which was estimated to be about 10% of cellular energy turnover. 
Glycoprotein, P-; Glycolysis; Verapamil; Multidrug resistance 
1. INTRODUCTION 
Selection of tumor cells for resistance to many 
natural product cytotoxic agents, including anthra- 
cyclines, vinca alkaloids and colchicine, mostly re- 
sults in overexpression of the m&Z gene [l-3], 
which encodes a plasma membrane protein, called 
P-glycoprotein. This protein appears to be homo- 
logous to bacterial transport proteins and has 12 
consensus transmembrane domains and two ATP- 
binding sites [4]. Since active efflux of drugs like 
anthracyclines is thought to be responsible for the 
MDR phenotype [5], it has been hypothesized that 
P-glycoproteins might function as an energy- 
dependent drug efflux pump of broad specificity 
for toxic lipophilic agents. Drugs that reverse 
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MDR, such as the prototype verapamil, are be- 
lieved to compete with the drug efflux mechanism 
[6], possibly by interaction with P-glycoproteins 
171. Recently we showed that verapamil induced net 
ATP hydrolysis in MDR cells and suggested that 
interaction of verapamil with P-glycoprotein im- 
poses a considerable cost in metabolic energy on a 
cell [8]. 
Independently it was suggested, based on ex- 
periments using the MDR human breast carcinoma 
cell line MCF-7/ADrR, that an increased rate of 
glycolysis in MDR cells might be related to in- 
creased energy-dependent drug detoxification [9]. 
In particular, increased anionic glutathione 
transferase activity was suggested to be a determi- 
nant for increased NADPH demand coupled to in- 
creased dependency on glucose metabolism and 
glycolytic rate in these cells [9,10]. 
Here, we provide evidence that increased energy 
consumption by the P-glycoprotein-verapamil in- 
teraction in MDR cells is compensated for by in- 
creased glycolysis. The pH dependence and 
specificity of this effect are investigated. 
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2. MATERIALS AND METHODS 2.5. Drugs 
2.1. Cells and cell culture 
Four human cancer cell lines and their MDR sublines, selected 
by exposure to increasing doses of doxorubicin, were used in 
these studies. MCF-7 and MCF-7/ADrR human breast cancer 
cells [lo], A2780 and 2780AD human ovarian cancer cells [l I], 
SW1573 and SW1573/500 human squamous lung cancer cells 
[12,13] and H-134 and H-134 AD human ovarian carcinoma 
cells [12,14] were routinely subcultured in Dulbecco’s modifica- 
tion of Eagle’s medium + 7.5% fetal calf serum, the resistance 
lines with doxorubicin until 8-12 days before experiments, as 
described 1151. All stocks of cells were free of mycoplasma on 
initiation of the experiments as tested with Hoechst stain 33258. 
All resistant cell lines expressed plasma membrane P-glycopro- 
tein, as checked with monoclonal antibodies JSB-1 1121 and 
MRK-16 1161. 
Nigericin, monensin, phorbol myristate acetate, diltiazem, 
nifedipine, oligomycin, vincristine, trifluoperazine and 
verapamil hydrochloride were from Sigma. Daunomycin was 
from Specia (Paris); amiloride from Merck, Sharp & Dohme; 
chloroquine from Bayer, cytochalasin B from Calbiochem and 
RO 1 l-2933/001 from Hoffmann-La Roche. 
3. RESULTS 
2.2. Lactate measurements 
Exponentially growing cells were harvested, washed in ice- 
cold phosphate-buffered saline and suspended in incubation 
medium at a cell density of 2 x lo6 cells/ml. The incubation 
medium was of the same composition as growth medium, in- 
cluding 4 mM glutamine and 5.6 mM D-glucose, without pH in- 
dicator and bicarbonate buffer, but with 20 mM Hepes (pH as 
indicated) and with 10% dialyzed fetal calf serum. Cells were in- 
cubated with drugs and extracted with perchloric acid. Super- 
natants were neutralized with KOH and stored at - 20°C until 
assayed. Lactate was measured by spectrophotometric deter- 
mination of NADH formation at 340 nm in the presence of ex- 
cess NAD’ and lactate dehydrogenase (Boehringer Mannheim, 
FRG) at pH 9.5. Because of reports that reducing equivalents 
derived from L-glutamine oxidation might be essential to drive 
lactate formation [17], in preliminary experiments the effect of 
omission of L-glutamine on lactate production in A2780 and 
278pD was determined. No differences were observed, in- 
dicating that in both cell lines D-glucose was the major source 
for lactate formation. 
Four cell lines with proven overexpression of P- 
glycoprotein were assayed for the effect of 
verapamil on glycolysis rate. Fig.1 shows that in- 
creased basal glycolysis rates were found in two 
MDR lines compared to the parent cell lines 
(fig.lC,D) but not in the other two (fig.lA,B). 
Verapamil significantly increased lactate formation 
in all four MDR lines, but had no effect in the 
parent lines. In fig.2 the concentration-effect curve 
for the effect of verapamil in 278vD is shown. 
Medium concentrations of verapamil as low as 
2 PM had a maximal effect, as observed previously 
for the effect of verapamil on depletion of cellular 
ATP concentrations, when respiration had been 
blocked [8]. Cellular oxygen consumption was 
1.38 f 0.08 and 1.31 + 0.17 (nmol Oz/min per lo6 
cells; means -t SD for 3 experiments) for A2780 
and 2780AD, respectively. It was found that 
verapamil up to 50pM did not affect cell respira- 
tion (not shown), indicating that there was no 
disturbance of ATP production from coupled ox- 
idative phosphorylation. 10 mM NaNs blocked 
respiration completely in both cell lines. 
2.3. Oxygen consumption 
Cellular oxygen consumption was measured with a YSI 5331 
oxygen probe (Yellow Springs Instrument Co.) and a Beckman 
model 0260 oxygen analyzer. A suspension of 2.5 x lo6 cells/ml 
medium was pre-incubated in the measuring vial at 37°C until a 
stable signal was obtained, after which the vessel was sealed. 02 
consumption was measured over 10 min, after which either 
saline (control) or drug was injected, and 02 consumption was 
recorded for 30 min. The probe was calibrated in air and in 
medium with sodium bisulfite added. 
2.4. Glutathione S-transferase assay 
Total glutathione S-transferase (EC 2.5.1.18) was assayed in 
cell extracts, solubilized in 0.05% Triton X-100 and thereafter 
sonicated [18]. Supernatants after centrifugation were in- 
cubated with 1 mM glutathione and 1 mM 1-chloro-2,4-dimtro- 
benzene in 0.2 M sodium phosphate buffer at pH 6.5 and 30°C. 
The absorbance at 340 nm was recorded for 5 min. Enzyme ac- 
tivity was calculated in nmol conjugate/min per mg protein. 
Protein was measured by the method of Bradford [19]. 
As pH-dependent mechanisms have been im- 
plicated in reversal of MDR, suggesting that 
resistance-modifying agents may act by a 
mechanism involving their accumulation in acidic 
cytoplasmic structures [20,21] and since small dif- 
ferences in intracellular pH are known to have a 
large effect on aerobic glycolysis in leukocytes [22] 
and in tumor cells [23,24], we investigated the pH 
dependence of the effects of verapamil on glyco- 
lytic rate in A2780 and 278eD cells. Firstly, the 
results show that the response of glycolysis to 
changes in pH is similar in both cell lines (fig.3). As 
a rule the steady-state cytoplasmic pH shifts are 
about 50% of the external pH shift [25]. An effect 
of verapamil is seen at all pH values in MDR cells, 
but not in sensitive cells, indicating that potentially 
intracellular pH differences between MDR and 
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Fig. I. Verapamil effect on cellular lactate formation. For lactate measurements, cells were incubated in complete medium plus 10% 
dialyzed fetal calf serum. Cellular lactate was measured with a lactate dehydrogenase assay after extraction. Data are from represen- 
tative experiments (duplicate samples) of 2-4 experiments per cell line. 
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Fig.2. Verapamil effect on cellular lactate formation (30 mm); 
concentration dependency. Data are means + SD of 2 ex- 
periments (performed in duplicate). 
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Effect of drugs on cellular lactate formation in 2780 cells 
pH.7.4 Drug Concentration 
GM) 
Verapamil 0.1 
Verapamil 0.25 
Verapamil 1 
Verapamil 8 
Ro 11-2933 8 
Trifluoperazine 5 
Diltiazem 32 
Chloroquine 50 
Amiloride 
Oligomycin 
Nigericin 
Monensin 
Cytochalasin B 
200 
4 @g/ml) 
10 
10 
20 
Daunomycin 
Daunomycin 
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PMA 
PMA 
100 
200 
100 
0.015 
0.15 
Fig.3. pH dependency of glycolysis in 2780 cells. Effects of 
verapamil. Data are from one of two similar experiments per 
cell line (duplicate samples). 
sensitive cells are not likely to be responsible for the 
effect. 
In order to establish the specificity of increases in 
glycolytic rate, we investigated the effects of a 
series of drugs with potential effects on cellular 
energy metabolism. Table 1 summarizes these ef- 
fects. In general, three groups of compounds could 
be identified. One group of drugs, like verapamil, 
induces either an increase in lactate formation in 
278pD cells exclusively or a greater increase in 
2780AD than in A2780 (chloroquine). A second 
group has similar effects in both cell lines. This 
group includes amiloride, an inhibitor of Na+/H+ 
exchange in various cell types [26]; monensin, an 
Na+/H+ ionophore, itself capable of increasing 
cytoplasmic pH [25]; nigericin, a mediator of 
K+/H+ exchange and able to uncouple oxidative 
phosphorylation [24]; the uncoupler oligomycin; 
and cytochalasin B, which lowers lactate formation 
in both cell lines to the same extent probably due to 
% control 
A2780 278tiD 
102* 5 
104k 6 
105 + la 
107* 1 
137+ 6” 178 + 19’ 
186 It 54” 186 * 53” 
149 k 16a 177 * 19” 
162 + 14a 175* ga 
199 f 23a 204 f 41a 
34 + 8a 34 f 12” 
106* 9 121 + 25 
141 f 14a 150 f 14a 
104 + 10 106+ 3 
104* 5 104* 7 
103 + 27 106+16 
102k 1 
113* 4* 
137 f 14= 
151 f 218 
133 * 15a 
158 + ? 
147 f 0” 
a Statistical significant difference from control (p < 0.05; paired 
f-test) 
Time of incubation was 30 min. Data are means + SD of 3-4 
experiments performed in duplicate. Control values were 
4.8 f 1.0 and 5.7 f 0.6 nmol lactate/min per lo6 cells (N=8) 
for 278tiD and A2780, respectively 
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Table 2 
Glutathione transferase activity in sensitive and MDR cell lines 
Cell line Glutathione 
transferase 
activity 
(nmol/min per 
Ratio MDR/sensitive cells 
Glutathione Lactate 
transferase formation 
mg protein) 
A2780 61 f la 
278tiD 123zt 3 2.0 0.8 
H-134 53* 6 
H-l 34AD 50* 0 0.95 0.8 
SW 1573 74+ 8 
SW 15731500 150 f 43 2.0 2.2 
MCF-7 3 (n= 1) 
MCF-7/ADrR 143 * 12 47.7 1.4 
a Data are means f SD of 2 experiments 
inhibition of glucose uptake [27]. A third group has 
no effect on lactate formation in either cell line. 
These include daunomycin and vincristine up to 
1OOpM and PMA. Since detoxification mecha- 
nisms, especially increased glutathione transferase 
activity, have been associated with the MDR 
phenotype [ 10,281, we investigated enzyme levels in 
the four pairs of cells and found a correlation with 
neither resistance nor glycolytic rates (table 2). 
4. DISCUSSION 
We show that low concentrations of resistance 
modifiers such as verapamil cause an increase in 
glycolytic rate in four MDR cell lines, probably as 
compensation for increased ATP consumption. 
These four MDR lines overexpress P-glycoprotein 
and in at least two of them (2780AD, SW1573/500) 
mdrl RNA is the only overexpressed species from 
the genes in the mdrl associated amplicon [29]. 
Since verapamil has been shown to bind to P-glyco- 
protein [7], its present effect on glycolysis is likely 
to be elicited via an energy-requiring interaction 
with P-glycoprotein, which possibly also mediates 
active verapamil transport. We obtained no 
evidence for differences in GST activities, which 
might account for this effect. 
Another compound known to interact with P- 
glycoprotein is PMA. In fact, PMA causes phos- 
phorylation of P-glycoprotein to similar levels as 
verapamil [30], which apparently does not require 
amounts of energy leading to a need for increased 
ATP production. Assuming 1 mol ATP/mol lac- 
tate and 5.6 mol ATP/mol 02 consumption at 
complete coupling of oxidative phosphorylation 
1311,. the calculated net ATP production in 2780AD 
cells was 12.5 nmol ATP/min per IO6 cells (38% 
contribution of glycolysis). From the difference in 
slope (fig.lA) it can be calculated that 8 PM 
verapamil caused an extra ATP turnover of 
1.5 nmol/min per lo6 cells, which is 12% of basal 
ATP turnover. This is a major ATP-consuming 
process when compared to other energy-requiring 
processes as estimated for Ehrlich ascites tumor 
cells on incubation in amino-acid-rich medium: 
about 30% for protein synthesis, 20% for 
Na+/K+-ATPase and approx. 10% for RNA syn- 
thesis, ATP-dependent proteolysis and Ca2+- 
ATPase [32]. 
Another finding in the present study concerns 
the effects of drugs like chloroquine, monensin and 
nigericin on cellular lactate formation. Lysosomo- 
tropic amines, such as chloroquine, and proton 
ionophores, which are known to alkalinize acidic 
vesicles [33], have been shown to increase drug sen- 
sitivity of cells by increasing anthracycline ac- 
cumulation [20,34,35]. Our studies suggest hat the 
action of these drugs is not different in MDR and 
parent, sensitive cells and therefore not directly 
dependent on P-glycoprotein overexpression. 
The present assay may provide a useful addi- 
tional test for agents that reverse MDR. The 
finding that verapamil also affects MDR cells also 
at pH 6.6 may be of clinical importance, since such 
a low pH appears to be a common feature in solid 
tumors [36]. Further, it would be interesting to ex- 
plore a possible relation between the major effects 
of resistance-reversing agents on cellular energy 
metabolism and increased cytostatic effects often 
observed for such drugs in MDR cells [37]. 
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